Treatment of primary mucosal head and neck squamous cell carcinoma using photodynamic therapy: results after 25 treated cases

Dilkes, M. G.; Benjamin, Ernst; Ovaisi, Shazia; Banerjee, Amrita

doi:10.1258/002221503322334558

Cited by 37 publications

(21 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dilkes treated five patients with T1-2 laryngeal tumors with Foscan PDT. Only one of the five patients had no recurrence of disease [22].…”

Section: Early Stage Head and Neck Cancer: Foscan (Mthpc)-mediated Pdtmentioning

confidence: 87%

“…Some patients received multiple PDT treatments. Of the 19 patients treated, 90% obtained a documented complete response and 10 of 19 patients remained free of disease with follow-up of 6-100 months [20][21][22]. Monnier treated four patients with Tis and T1 lesions of the oral cavity with a complete response [23].…”

Section: Early Stage Head and Neck Cancer: Foscan (Mthpc)-mediated Pdtmentioning

confidence: 99%

See 1 more Smart Citation

Advances in photodynamic therapy for the treatment of head and neck cancers

Biel

2006

Lasers Surg Med

135

View full text Add to dashboard Cite

Photodynamic therapy (PDT) is an FDA-approved minimally invasive medical treatment modality that utilizes light in the presence of oxygen to activate photosensitizing agents that are relatively selectively concentrated in abnormal or neoplastic cells resulting in cell death. At the present time, PDT has been approved for clinical treatment in the United States, European Union, Canada, Russia, and Japan. In the United States, US Food and Drug administration approval has been given for the use of PDT in the treatment of Barrett's esophagus, obstructing esophageal carcinoma and early and obstructing tracheobronchial carcinoma using the photosensitizer Photofrin; actinic keratosis using the photosensitizer Levulan (aminolevulinic acid); and macular degeneration using the photosensitizer BPD. In the EU the above noted indications have also been approved in addition to the treatment of early head and neck cancers and palliative treatment of head and neck cancer using the photosensitizer Foscan; and treatment of basal and squamous cell skin cancers using the photosensitizer Metvix.

show abstract

“…Dilkes treated five patients with T1-2 laryngeal tumors with Foscan PDT. Only one of the five patients had no recurrence of disease [22].…”

Section: Early Stage Head and Neck Cancer: Foscan (Mthpc)-mediated Pdtmentioning

confidence: 87%

Section: Early Stage Head and Neck Cancer: Foscan (Mthpc)-mediated Pdtmentioning

confidence: 99%

Advances in photodynamic therapy for the treatment of head and neck cancers

Biel

2006

Lasers Surg Med

135

View full text Add to dashboard Cite

show abstract

“…To date, this is the only photosensitizer that has been evaluated in multi-institutional trials for the treatment of head and neck cancers. Numerous single investigator trials have demonstrated the efficacy of Foscan PDT in treating head and neck cancers (20)(21)(22)(23)(24)(25).…”

Section: Early Stage Head and Neck Cancer: Foscan (Mthpc)-mediated Pdtmentioning

confidence: 99%

Photodynamic Therapy of Head and Neck Cancers

Biel

2010

Methods in Molecular Biology

108

View full text Add to dashboard Cite

Over 1,500 patients have been treated with PDT using Photofrin, HPD, ALA, or Foscan for head and neck cancers. These patients include a mixture of presentations including primary, recurrent, and metastatic lesions. The predominant histology is squamous cell carcinoma, but other histologies treated include mucosal melanoma, Kaposi's sarcoma, adenocarcinoma, metastatic breast carcinoma, and adenoid cystic carcinoma. Several multi-institutional phase II clinical trials evaluating PDT treatment of head and neck cancers have demonstrated the efficacy of this minimally invasive therapy in the treatment of early oropharyngeal primary and recurrent cancers as well as the palliative treatment of refractory head and neck cancers. Patients with early stage cancers or early recurrences in the oral cavity and larynx (Cis, T1, T2) tend to have an excellent response to PDT. Of 518 patients treated with Cis, T1, or T2 cancers of the oral cavity, larynx, pharynx, and nasopharynx, 462 (89.1%) obtained a complete clinical response after one PDT treatment. Laryngeal cancers, comprising 171 patients in this group, obtained a durable complete response rate of 89% with up to a 16-year follow-up. Photodynamic therapy is as effective as conventional therapies for the treatment of early (Cis, T1, T2) squamous cell cancers of the head and neck. It is also a promising therapy to be used in association with surgery to increase tumor-free margins and therefore increase cure rates.

show abstract

“…The current treatment standards include surgery, chemotherapy and radiotherapy. But all of these methods may cause serious side effects, often permanent, that hinder normal functioning of the body [26]. Extensive radiotherapy may cause mucositis, xerostomia, loss of taste and smell and even osteoradionecrosis.…”

Section: Cancer Therapymentioning

confidence: 99%

“…It is assigned for the palliative treatment of advanced head and neck cancers that did not respond to primary therapy [5]. It is usually injected at a dose of 0.15 mg/kg and activated with light at 652 nm after 4 days of delay [26]. The treatment protocol based on the use of this photosensitizer is directed to patients who cannot be subjected to surgery, chemotherapy or radiotherapy.…”

Section: Cancer Therapymentioning

confidence: 99%